(Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q4)Dec 31, 2022 | (Q3)Sep 30, 2022 | (Q2)Jun 30, 2022 | |
---|---|---|---|---|---|---|---|---|---|---|
Operating Cash Flow (Indirect Method) | ||||||||||
Cash flow from continuing operating activities | 18.53%315.59K | 1,541.92%937.34K | -142.80%-59.35K | 309.56%851.34K | 54.97%-120.9K | 1,368.15%266.25K | -94.82%57.09K | 902.52%138.69K | -63.86%207.87K | -355.78%-268.47K |
Net income from continuing operations | 104.27%15.57K | -363.44%-4.14M | -827.01%-3.8M | 94.41%-8.06K | -97.98%36.22K | 38.98%-364.62K | 3,011.88%1.57M | 258.05%522.73K | -346.44%-144.13K | 3,806.58%1.79M |
Operating gains losses | -1.24%-28.85K | -59.55%13.09K | --11.4K | --2.22K | --27.97K | ---28.49K | 115.70%32.36K | ---- | ---- | ---- |
Depreciation and amortization | -5.28%220.21K | 13.54%920.88K | 10.76%242.5K | 28.41%235.75K | 3.14%210.13K | 13.51%232.5K | 51.66%811.09K | 35.13%218.94K | -11.05%183.59K | 78.00%203.74K |
Asset impairment expenditure | ---- | 2,723.22%3.48M | ---- | ---- | ---- | ---- | 437.83%123.29K | ---- | ---- | ---- |
Remuneration paid in stock | -113.02%-11.95K | ---- | ---- | --0 | ---205.27K | --91.77K | ---- | ---- | 35.97%24.49K | ---- |
Remuneration paid in stock | ---- | --0 | --0 | --0 | ---- | ---- | -73.27%48.31K | -97.66%2.41K | -94.67%3.56K | -13.95%3.84K |
Other non cashItems | -27.85%18.83K | 105.65%115.97K | 275.10%49.3K | -456.34%-24.18K | 103.11%64.76K | 156.56%26.09K | -6,740.08%-2.05M | 13.63%13.14K | -41.23%6.79K | -1,073.89%-2.08M |
Change In working capital | -67.06%101.78K | 214.54%543.27K | 79.29%-156.65K | 383.35%645.62K | -46.08%-254.7K | -4.36%309K | -172.80%-474.28K | -1,022.74%-756.58K | -37.57%133.57K | -27.47%-174.36K |
-Change in receivables | 210.23%46.69K | 158.14%75.65K | -97.52%-461.17K | 442.68%746.43K | -21.48%-167.26K | -116.11%-42.36K | -93.02%29.3K | -23.02%-233.49K | -66.79%137.55K | 13.98%-137.68K |
-Change in prepaid assets | -146.39%-65.43K | 144.27%243.56K | 110.86%61.5K | 44.09%178.82K | -722.17%-137.83K | 254.18%141.06K | -716.15%-550.22K | -4,438.05%-566.07K | 825.61%124.11K | 40.25%-16.76K |
-Change in payables and accrued expense | -103.48%-5.86K | 431.11%150.8K | 17,537.40%231.74K | -277.65%-244.01K | -310.50%-5.12K | 75.97%168.2K | -89.51%28.39K | -100.47%-1.33K | 57.21%-64.61K | -101.57%-1.25K |
-Change in other working capital | 200.25%126.38K | 301.54%73.26K | -74.55%11.27K | 43.87%-35.62K | 397.42%55.51K | -24.93%42.09K | -35.27%18.24K | 292.19%44.3K | -1.35%-63.47K | 33.87%-18.67K |
Cash from discontinued investing activities | ||||||||||
Operating cash flow | 18.53%315.59K | 1,541.92%937.34K | -142.80%-59.35K | 309.56%851.34K | 54.97%-120.9K | 1,368.15%266.25K | -94.82%57.09K | 902.52%138.69K | -63.86%207.87K | -355.78%-268.47K |
Investing cash flow | ||||||||||
Cash flow from continuing investing activities | -2.89%-171.12K | 23.72%-592.07K | 35.16%-138.84K | -21.85%-205.47K | 59.13%-81.45K | 14.31%-166.32K | 81.10%-776.14K | 46.78%-214.13K | 7.85%-168.62K | 94.05%-199.3K |
Net PPE purchase and sale | 91.50%-1.08K | 72.97%-28.31K | 28.23%-9.33K | 80.07%-5.38K | 97.07%-909 | 62.36%-12.69K | 25.52%-104.77K | 45.84%-13K | 17.43%-27.01K | 61.68%-31.03K |
Net intangibles purchas and sale | -10.69%-170.04K | 16.03%-563.76K | 35.61%-129.51K | -41.29%-200.08K | 52.13%-80.54K | 4.20%-153.62K | -16.12%-671.37K | -32.96%-201.13K | -49.77%-141.61K | -4.48%-168.27K |
Cash from discontinued investing activities | ||||||||||
Investing cash flow | -2.89%-171.12K | 23.72%-592.07K | 35.16%-138.84K | -21.85%-205.47K | 59.13%-81.45K | 14.31%-166.32K | 81.10%-776.14K | 46.78%-214.13K | 7.85%-168.62K | 94.05%-199.3K |
Financing cash flow | ||||||||||
Cash flow from continuing financing activities | 55.32%-87.4K | -198.10%-491.09K | -3.52%94.4K | -277.57%-664.3K | -28.61%274.39K | -200.65%-195.59K | -76.92%500.59K | 200.70%97.85K | -4.13%-175.94K | -84.41%384.35K |
Net issuance payments of debt | 63.91%-70.6K | -197.31%-442.77K | 45.86%142.72K | -277.57%-664.3K | -28.61%274.39K | -231.49%-195.59K | -78.83%455K | 188.41%97.85K | -2.31%-175.94K | -84.41%384.35K |
Proceeds from stock option exercised by employees | ---- | --0 | --0 | --0 | ---- | ---- | 133.53%45.59K | -99.99%2 | --0 | --0 |
Net other financing activities | ---16.8K | ---48.32K | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- |
Cash from discontinued financing activities | ||||||||||
Financing cash flow | 55.32%-87.4K | -198.10%-491.09K | -3.52%94.4K | -277.57%-664.3K | -28.61%274.39K | -200.65%-195.59K | -76.92%500.59K | 200.70%97.85K | -4.13%-175.94K | -84.41%384.35K |
Net cash flow | ||||||||||
Beginning cash position | -49.14%150.93K | -61.37%296.75K | -26.54%254.72K | -53.21%284.18K | -73.87%204.6K | -61.37%296.75K | -47.45%768.25K | -72.74%346.74K | -41.40%607.29K | -57.90%783.16K |
Current changes in cash | 159.66%57.07K | 33.25%-145.82K | -563.10%-103.79K | 86.52%-18.42K | 186.35%72.04K | -360.98%-95.65K | 73.87%-218.46K | 104.61%22.41K | -161.24%-136.7K | 91.13%-83.43K |
Effect of exchange rate changes | --0 | --0 | 99.99%-7 | 91.09%-11.04K | 108.15%7.53K | -90.16%3.51K | -277.56%-253.04K | -302.89%-72.41K | -1,109.20%-123.85K | -179.41%-92.44K |
End cash Position | 1.66%208K | -49.14%150.93K | -49.14%150.93K | -26.54%254.72K | -53.21%284.18K | -73.87%204.6K | -61.37%296.75K | -61.37%296.75K | -72.74%346.74K | -41.40%607.29K |
Free cash from | 44.56%144.47K | 148.02%345.27K | -162.72%-198.19K | 1,545.70%645.87K | 56.74%-202.35K | 146.46%99.93K | -287.99%-719.05K | 53.27%-75.44K | -91.24%39.25K | -55.43%-467.78K |
Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
Audit Opinions | -- | Unqualified Opinion | -- | -- | -- | -- | Unqualified Opinion | -- | -- | -- |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.